BMRN
BIOMARIN PHARMACEUTICAL INC
NASDAQ · Healthcare · Biotechnology · US
$63.94
−1.75%Year over year
Reported trailing growth
- Revenue
- +11.2%
- EBITDA
- -58.7%
- EBIT
- -64.8%
- EPS
- -89.0%
- Free cash flow
- +6.0%
- Operating cash flow
- +11.8%
Forward estimates
Based on analyst estimates
- Revenue
- +26.9%
- EBITDA
- +394.1%
- EPS
- +1526.8%
Three-year CAGR
- Revenue
- +15.4%
- EBITDA
- +29.2%
- EBIT
- +49.1%
- Net income
- +35.1%
- EPS
- +33.8%
- Free cash flow
- +136.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026